These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17699465)

  • 1. New technologies in peritoneal dialysis.
    Bargman JM
    Clin J Am Soc Nephrol; 2007 May; 2(3):576-80. PubMed ID: 17699465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome.
    Lee HY; Choi HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Kim MJ; Shin SK
    Nephrol Dial Transplant; 2006 Oct; 21(10):2893-9. PubMed ID: 16957012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of peritoneal dialysis technology on patient care.
    Diaz-Buxo JA; Crawford-Bonadio TL
    Adv Perit Dial; 2005; 21():112-4. PubMed ID: 16686298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biocompatible fluids for peritoneal dialysis: do they have a clinical impact?].
    Feriani M
    G Ital Nefrol; 2007; 24(4):320-6. PubMed ID: 17659503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Optimal use of peritoneal dialysis fluids in type 2 diabetes mellitus patients].
    Ryckelynck JP; Allard C; Cousin M; Hurault de Ligny B; El Haggan W; Lobbedez T
    Nephrol Ther; 2006 Jan; 2 Suppl 1():S82-5. PubMed ID: 17378147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rethinking the peritoneal dialysis prescription: results of recent studies.
    Bargman JM
    Nephrology (Carlton); 2006 Apr; 11(2):85-9. PubMed ID: 16669966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving cycler prescriptions in peritoneal dialysis through informatic profiling.
    Mujais S; Story K
    Adv Chronic Kidney Dis; 2007 Jul; 14(3):263-8. PubMed ID: 17603980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Standard methods of peritoneal dialysis (PD) and standard peritoneal dialysis solutions in the future in Japan].
    Nakamoto H
    Nihon Jinzo Gakkai Shi; 2009; 51(7):864-74. PubMed ID: 19928560
    [No Abstract]   [Full Text] [Related]  

  • 9. Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis.
    Higuchi C; Nishimura H; Sanaka T
    Ther Apher Dial; 2006 Aug; 10(4):372-9. PubMed ID: 16911191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effects of peritoneal dialysis solutions in the mesenteric microcirculation.
    Frajewicki V; Brod V; Kushnir D; Kohan R; Bitterman H
    Transl Res; 2009 May; 153(5):249-56. PubMed ID: 19375686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transport of peritoneal membrane assessed before and after the start of peritoneal dialysis.
    La Milia V; Limardo M; Cavalli A; Crepaldi M; Locatelli F
    Nephrol Dial Transplant; 2009 Sep; 24(9):2894-8. PubMed ID: 19349295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of peritoneal dialysis solutions.
    Crawford-Bonadio TL; Diaz-Buxo JA
    Nephrol Nurs J; 2004; 31(5):499-507, 520; quiz 508-9. PubMed ID: 15518252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
    Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
    Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients.
    Cho Y; Johnson DW; Badve SV; Craig JC; Strippoli GF; Wiggins KJ
    Kidney Int; 2013 Nov; 84(5):969-79. PubMed ID: 23698236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal dialysis: past, present, and future.
    Oreopoulos DG; Ossareh S; Thodis E
    Iran J Kidney Dis; 2008 Oct; 2(4):171-82. PubMed ID: 19377234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the use of neutral pH, low glucose degradation product peritoneal dialysis fluids lead to better patient outcomes?
    Cho Y; Johnson DW
    Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):192-7. PubMed ID: 24378773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucotoxicity in peritoneal dialysis--solutions for the solution!
    Holmes CJ
    Adv Chronic Kidney Dis; 2007 Jul; 14(3):269-78. PubMed ID: 17603981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal dialysis catheter insertion by interventional nephrologists.
    Alvarez AC; Salman L
    Adv Chronic Kidney Dis; 2009 Sep; 16(5):378-85. PubMed ID: 19695506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing the formation of glucose degradation products in peritoneal dialysis solutions by ultrahigh temperature ohmic heating.
    Shapira A; Shazman A; Ungar Y; Shimoni E
    Mol Nutr Food Res; 2007 Apr; 51(4):473-8. PubMed ID: 17390399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protecting the peritoneal membrane in dialyzed patients.
    Grzegorzewska AE
    Adv Med Sci; 2006; 51():191-6. PubMed ID: 17357307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.